Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

Arthritis and Rheumatism

Volumn 44, Issue 1, 2001, Pages 180-185

  Dougados, Maxime ^a   Béhier, Jehan Michel ^b   Jolchine, Irne ^b   Calin, Andrei ^c   Van Heijde, Désirée Der ^d   Olivieri, Ignazio ^e   Zeidler, Henning ^f   Herman, Hélène ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Medical Department   (France)

^c ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e SAN CARLO HOSPITAL   (Italy)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; KETOPROFEN; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIGASTRIC PAIN; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECTUM HEMORRHAGE; STOMACH ULCER;

EID: 0035150435     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K     Document Type: Article

References (22)

1. Seronegativc spondylarthropathies
2. Diagnostic features of ankylosing spondylitis
3. Diagnosis and monitoring of spondylarthropathy
4. Current guidelines for the drug treatment of ankylosing spondylitis
5. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
6. Synthesis and biological evaluation of the 1,5diarypyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib)
7. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
8. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
9. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison
10. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
11. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index
12. Spondylarthrite ankylosante et anti-inflammatoires
13. A double blind crossover placebo controlled trial of ximoprofen in AS
14. Ximoprofen in ankylosing spondylitis: A double blind placebo controlled dose ranging study
15. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal antiinflammatory drug trial
16. Preliminary core sets for endpoints in ankylosing spondylitis
17. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis: Progress report of the ASAS Working Group
18. Ketoprofen: A preliminary report of its pharmacological activity and therapeutic efficacy in rheumatic disorders
19. Ketoprofen: A review of its pharmacologic and clinical properties
20. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis
21. The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis